Resumen de Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy
Javier de Castro Carpeño, José Luis González Larriba, Sergio Vázquez Estévez, Bartomeu Massuti Sureda, José Miguel Sánchez Torres, Manuel Dómine Gómez, Pilar Garrido López, Antonio Calles, Ángel Artal Cortés, Ricardo Collado Martín, María Rosario García Campelo, M. Sereno Moyano, Margarita Majem, José Antonio Macías Cerrolaza, Óscar Juan Vidal, José Gómez Codina, Berta Hernández Marín, Martin Lázaro Quintela, A. L. Ortega Granados, Manuel Cobo Dols, José Manuel Trigo Pérez, Enric Carcereny Costa, C. Rolfo, S. Maciá Escalante, José Muñoz Langa, Pilar Diz Taín, Miguel Méndez Ureña, F. E. Rosillo Fernández, Luis Paz-Ares Rodríguez, J. V. Cardona, Dolores Isla Casado
Background/Aim First-line bevacizumab-based therapies have been shown to improve clinical outcomes in patients with non-squamous non-small-cell lung cancer (NSCLC). We aimed to descriptively analyse patients with non-squamous NSCLC who received a long-term period of maintenance bevacizumab.
Patients and methods This retrospective study included 104 patients who had already reached a progression-free survival (PFS) of at least 9 months.
Results Median overall survival and PFS were 30.7 and 15.1 months, respectively. The overall response rate was 83 %. Weight loss ≤5 %, ECOG PS = 0, or low number of metastatic sites seem to be predictive factors of good evolution. The incidence of bevacizumab-related adverse events appeared to be similar as the previous studies.
Conclusion Our findings show that there is a long-term survivor group whom the administration of bevacizumab resulted in a relevant prolongation of response without new safety signals. Due to the population heterogeneity, it was not possible to identify the standardised predictive factors.
